Pramipexole dihydrochloride hydrate
Modify Date: 2024-01-02 18:00:22
Pramipexole dihydrochloride hydrate structure
|
Common Name | Pramipexole dihydrochloride hydrate | ||
|---|---|---|---|---|
| CAS Number | 191217-81-9 | Molecular Weight | 302.264 | |
| Density | N/A | Boiling Point | 378ºC at 760 mmHg | |
| Molecular Formula | C10H21Cl2N3OS | Melting Point | 290 °C(dec.) | |
| MSDS | N/A | Flash Point | 182.4ºC | |
Use of Pramipexole dihydrochloride hydratePramipexole dihydrochloride hydrate is a selective dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride hydrate can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS). Pramipexole dihydrochloride hydrate can cross the blood-brain barrier (BBB)[1][2][3]. |
| Name | pramipexole hydrochloride |
|---|---|
| Synonym | More Synonyms |
| Description | Pramipexole dihydrochloride hydrate is a selective dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride hydrate can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS). Pramipexole dihydrochloride hydrate can cross the blood-brain barrier (BBB)[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
D2 Receptor:3.9 nM (Ki) D3 Receptor:0.5 nM (Ki) D4 Receptor:1.3 nM (Ki) D2-type receptors:2.2 nM (Ki) |
| In Vitro | Pramipexole dihydrochloride hydrate (0.01-10 μM; 72 hours) produces dose-dependent increases of dendritic arborization and soma size[3]. Pramipexole dihydrochloride hydrate attenuates levodopa-induced toxicity in mesencephalic cultures, suggests that pramipexole may be cytoprotective to dopamine neurons in tissue culture[4]. |
| In Vivo | Pramipexole dihydrochloride hydrate (0.25-1 mg/kg; i.p.) significantly reduces the infarction volume in animals[5]. Pramipexole dihydrochloride hydrate improves neurological recovery[5]. Pramipexole dihydrochloride hydrate prevents ischemic cell death via mitochondrial pathways in ischemic stroke[5]. Animal Model: Male Wistar rats weighing 250-300 g (16-18 weeks old)[5] Dosage: 0.25 mg/kg, 1 mg/kg Administration: Intraperitoneal injection, at 1 hour, 6 hours, 12 hours, 18 hours post-occlusion Result: Decreased infarction volume as compared to tMCAO (transient middle cerebral artery occlusion)-only animals. |
| References |
| Boiling Point | 378ºC at 760 mmHg |
|---|---|
| Melting Point | 290 °C(dec.) |
| Molecular Formula | C10H21Cl2N3OS |
| Molecular Weight | 302.264 |
| Flash Point | 182.4ºC |
| Exact Mass | 301.078247 |
| PSA | 88.41000 |
| LogP | 4.09400 |
| Vapour Pressure | 9.93E-11mmHg at 25°C |
| Storage condition | 2-8°C |
| Water Solubility | Freely soluble in water, soluble in methanol, sparingly soluble or slightly soluble in ethanol (96 per cent), practically insoluble in methylene chloride. |
| Hazard Codes | Xi |
|---|---|
| RIDADR | NONH for all modes of transport |
| RTECS | DL3375000 |
| HS Code | 2934999090 |
| HS Code | 2934999090 |
|---|---|
| Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N-propyl-, (6S)-, hydrochloride, hydrate (1:2:1) |
| (6S)-N-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine dihydrochloride hydrate |
| (S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole Dihydrochloride Monohydrate |
| Pramipexole dihydrochloride |
| Pramipexole dihydroch |
| pramipexole 2hcl monohydrate |
| (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride PPX dihydrochloride |
| Pramipexole Dihydrochloride Monohydrate |
| Pramipexole |